Literature DB >> 11749044

FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.

F Lim1, F Hernández, J J Lucas, P Gómez-Ramos, M A Morán, J Avila.   

Abstract

The tauopathies, which include Alzheimer's disease (AD) and frontotemporal dementias, are a group of neurodegenerative disorders characterized by filamentous Tau aggregates. That Tau dysfunction can cause neurodegeneration is indicated by pathogenic tau mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). To investigate how Tau alterations provoke neurodegeneration we generated transgenic mice expressing human Tau with four tubulin-binding repeats (increased by FTDP-17 splice donor mutations) and three FTDP-17 missense mutations: G272V, P301L, and R406W. Ultrastructural analysis of mutant Tau-positive neurons revealed a pretangle appearance, with filaments of Tau and increased numbers of lysosomes displaying aberrant morphology similar to those found in AD. Lysosomal alterations were confirmed by activity analysis of the marker acid phosphatase, which was increased in both transgenic mice and transfected neuroblastoma cells. Our results show that Tau modifications can provoke lysosomal aberrations and suggest that this may be a cause of neurodegeneration in tauopathies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11749044     DOI: 10.1006/mcne.2001.1051

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  62 in total

1.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

2.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

3.  Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia.

Authors:  Julia Terreros-Roncal; Miguel Flor-García; Elena P Moreno-Jiménez; Noemí Pallas-Bazarra; Alberto Rábano; Nirnath Sah; Henriette van Praag; Damiana Giacomini; Alejandro F Schinder; Jesús Ávila; Maria Llorens-Martín
Journal:  J Neurosci       Date:  2019-05-27       Impact factor: 6.167

Review 4.  Tau in neurodegenerative diseases: tau phosphorylation and assembly.

Authors:  J Avila; M Pérez; F Lim; A Gómez-Ramos; F Hernández; J J Lucas
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

5.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 6.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

Review 7.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 8.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Authors:  Jennifer B Paulson; Martin Ramsden; Colleen Forster; Mathew A Sherman; Eileen McGowan; Karen H Ashe
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

Review 10.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.